Identifying neurocognitive disorders in primary care settings

Identification of Neurocognitive Disorders by General Practitioners in Primary Care

Not applicable Interventional Hospices Civils de Lyon · NCT03678376

This study is testing a new way for doctors to spot early signs of brain disorders in older patients during regular check-ups to help them get the care they need sooner.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment1018 (estimated)
Ages65 Years and up
SexAll
SponsorHospices Civils de Lyon Academic / other
Locations1 site (Villeurbanne)
Trial IDNCT03678376 on ClinicalTrials.gov

What this trial studies

This study aims to improve the early diagnosis of neurocognitive disorders (NCD) in patients aged 65 and older by training general practitioners to recognize cognitive complaints and at-risk behaviors. It focuses on implementing cognitive and functional assessments during routine visits to facilitate timely intervention. The goal is to reduce the number of undiagnosed cases and enhance the quality of life for patients and caregivers by enabling secondary or tertiary prevention strategies. The study is based on recommendations from various French health authorities and organizations.

Who should consider this trial

Good fit: Ideal candidates are patients aged 65 and over who express cognitive complaints or exhibit at-risk behaviors related to neurocognitive disorders.

Not a fit: Patients who are already diagnosed with neurocognitive disorders or those who are institutionalized will not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could lead to earlier diagnosis and better management of neurocognitive disorders, improving patient outcomes and quality of life.

How similar studies have performed: Other studies have shown that early identification and intervention in neurocognitive disorders can significantly improve patient outcomes, suggesting this approach has potential for success.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patient aged 65 and over,
* Patient expressing a cognitive complaint (memory, language, sense of time and place disorientation for example) to his/her general practitioner; the complaint can be provided by an informal caregiver and /or, presenting with "at risk" behaviour\* possibly related to a NCD (mistaking medicine or forgetting medical consultation, forgetting hot meals, losing him/herself for example...),
* Patients able to understand the specifications of the study and to realize it (vision, audition, language...)
* Patient who has been informed and has consented to the study (himself/herself and by a trusted person/a family member if applicable) as established by the "article L. 1121-8 du Code de la Santé Publique".
* Registered with a social security system

Exclusion Criteria:

* Institutionalized patients
* Patients unable to understand the purpose of the study,
* Patients with neurocognitive disorders already diagnosed
* Patients under legal protection
* Patients with auditory or visual disorders which do not allow to perform the assessment
* Patients who do not want to go to the Memory Clinic
* Patients with severe disease commit the prognosis in relatively short term
* Participation to another trial that would interfere with the present study
* Patient with severe anxiety or depression preventing from any reliable neuropsychological assessment.

Where this trial is running

Villeurbanne

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Neurocognitive DisordersDiagnostic strategyNeurocognitive disordersPrimary Care
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.